Overview

Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma

Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with recurrent glioblastoma or recurrent gliosarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Rogel Cancer Center
Treatments:
Mycophenolic Acid